Annual Reports in Medicinal Chemistry, Volume 37
1st Edition
Secure Checkout
Personal information is secured with SSL technology.Free Shipping
Free global shippingNo minimum order.
Table of Contents
I. CENTRAL NERVOUS SYSTEM DISEASES
Section Editor: David W. Robertson, Pfizer Global Research & Development, Ann Arbor, MI
- Promise and Progress of Central G-Protein Coupled Receptor Modulators 1 for Obesity Treatments Brian L. Largent, Albert J. Robichaud and Keith J. Miller, Bristol-Myers Squibb Company, Wilmington, Delaware
- Attention Deficit Hyperactivity Disorder: Pathophysiology and Design of 11 New Treatments Shelly A. Glase, Larry D. Wise and David W. Robertson, Pfizer Global Research and Development, Ann Arbor, Michigan
- 5-HT2C Receptor Modulators: Progress in Development of 21
New CNS Medicines
Larry E. Fitzgerald and Michael D. Ennis, Pharmacia Corporation, Kalamazoo, Michigan
- Emerging Themes in Alzheimer's Disease Research: Paradigm Shift in Drug Discovery 31 Todd Morgan, School of Gerontology, University of Southern California, Los Angeles, California and Grant A. Krafft, Acumen Pharmaceuticals, Glenview, Illinois
II. CARDIOVASCULAR AND PULMONARY DISEASES
Section Editor: William J. Greenlee, Schering-Plough Research Institute, Kenilworth, New Jersey
- Recent Advances in Pulmonary Hypertension Therapy 41
Russell A. Bialecki, AstraZeneca Pharmaceuticals, Wilmington, Delaware
- Phosphodiesterase 5 Inhibitors 53
Andrew W. Stamford, Schering-Plough Research Institute, Kenilworth, New Jersey
- Antagonists of VLA-4 65
George W. Holland, Ronald J. Biediger, and Peter Vanderslice, Texas Biotechnology Corporation, Houston, Texas
- Purine and Pyrimidine Nucleotide (P2) Receptors 75 Kenneth A. Jacobson, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
- Anticoagulants: Inhibitors of the Factor VIIa/
Tissue Factor Pathway 85
Leslie A. Robinson and Eddine M. K. Saiah, Deltagen Research Laboratories, San Diego, California
III. CANCER AND INFECTIOUS DISEASES
Section Editor: Jacob J. Plattner, Chiron Corporation, Emeryville, California
The Prospect for Microbial Genomics Providing Novel, Exploitable, 95 Antibacterial Targets
Thomas J. Dougherty, Pfizer Global Research & Development, Groton, Connecticut and John F. Barrett, Merck Research Laboratories, Rahway, New JerseyThe Chemistry and Biology of Tetracyclines 105
Mark L. Nelson, Paratek Pharmaceuticals, Inc., Boston, Massachusetts
- Intracellular Signaling Targets for Cancer Chemosensitization 115
Thomas G. Gesner and Stephen D. Harrison, Chiron Corporation, Emeryville, California
- Emerging Microtubule Stabilizing Agents for Cancer Chemotherapy 125
David C. Myles, Kosan Biosciences, Inc., Hayward, California
- Antiviral Agents 133 Nicholas A. Meanwell, John F. Kadow and Paul M. Scola, The Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford, Connecticut
- Aerosol Delivery of Antibiotics 149
Peter B. Challoner, Chiron Corporation, Emeryville, California
IV. IMMUNOLOGY, ENDOCRINOLOGY AND METABOLIC DISEASES
Section Editor: William K. Hagmann, Merck Research Laboratories, Rahway, New Jersey
- Therapeutic Applications of Non-peptidic d-Opioid Agonists 159
Graham N. Maw and Donald S. Middleton, Pfizer Global Research and Development, Department of Discovery Chemistry, Sandwich, Kent
- Selective Glucocorticoid Receptor Modulators 167
Michael J. Coghlan*, Steven W. Elmore†, Philip R. Kym† and Michael E. Kort†, *Eli Lilly and Company, Discovery Chemistry Research & Technologies, DC , †Lilly Corporate Center, Indianapolis, Indiana, Abbott Laboratories, Global Pharmaceutical Research and Development, Illinois
- Inhibitors of p38 a MAP Kinase 177
Sarvajit Chakravarty and Sundeep Dugar, Scios Inc. Sunnyvale, California
V. TOPICS IN BIOLOGY
Section Editor: Janet M. Allen, Inpharmatica, London, United Kingdom
- Expanding and Exploring Cellular Pathways for Novel Drug Targets 187 Malcolm P. Weir, John P. Overington and Marlon Schwarz, Inpharmatica Ltd., London,
- Searching for Alzheimer's Disease Therapies In Your Medicine Cabinet: 197 The Epidemiological and Mechanistic Case For NSAIDs and Statins Robert B. Nelson, Pfizer Global Research and Development, Groton, Connecticut
- Matrix Metalloproteinases and the Potential Therapeutic Role for Matrix 209
Metalloproteinase Inhibitors in Chronic Obstructive Pulmonary Disease Kevin M. Bottomley and Maria G. Belvisi, Inpharmatica, London and Respiratory Pharmacology, Cardiothoracic Surgery, Imperial College School of Medicine, National Heart and Lung Institute, London
- Fc Receptor Structure and the Design of Anti-inflammatories: New 217 Therapeutics For Autoimmune Disease. Geoffrey A. Pietersz, Maree S. Powell, Paul A. Ramsland and P. Mark Hogarth, Austin Research Institute, Austin and Repatriation Medical Center, Victoria, Australia
- Tumor classification for tailored cancer therapy 225 Fiona McLaughlin and Nick LaThangue, Prolifix Ltd, Abingdon, Oxon
VI. TOPICS IN DRUG DESIGN AND DISCOVERY
Section Editor: George L. Trainor, DuPont Pharmaceuticals Company, Wilmington, Delaware
- Advances in the Discovery and Characterization of Ion Channel 237
Modulators: Focus on Potassium Channels
Valentin K. Gribkoff and John E. Starrett, Jr., Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut - Microwave-Assisted Chemistry as a Tool for Drug Discovery 247
Carolyn D. Dzierba and Andrew P. Combs, Bristol-Myers Squibb Co. Experimental Station, Wilmington, Delaware
VII. TRENDS AND PERSPECTIVES
Section Editor: Annette M. Doherty, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France
- To Market, To Market - 2001 257
Patrick Bernardelli, Bernard Gaudillière and Fabrice Vergne, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France
- Biosimulation: Dynamic Modeling of Biological Systems 279
Kevin Hall, Rebecca Baillie, and Seth Michelson, Entelos Inc., Menlo Park, California
COMPOUND NAME, CODE NUMBER AND SUBJECT INDEX, VOLUME 37 289
CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUMES 1-37 297
CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001 315
CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001, BY INDICATION 331
Description
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
Readership
Medicinal, pharmaceutical, and organic chemists.
Details
- No. of pages:
- 364
- Language:
- English
- Copyright:
- © Academic Press 2003
- Published:
- 2nd October 2002
- Imprint:
- Academic Press
- Hardcover ISBN:
- 9780120405374
- eBook ISBN:
- 9780080916224
Reviews
"This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." —ENZYMOLOGIA "This book is strongly recommended for researchers, teachers, students, administrators—in short, anyone whose interests impinge on medicinal chemistry. In view of the work's documented reference value, it is a must for inclusion in the scientist's personal library." —JOURNAL OF MEDICINAL CHEMISTRY "All topics are covered in sufficient depth, with extensive references, to allow either the specialist or the novice to be informed of the latest developments in a particular area of medicinal chemistry." —JOURNAL OF PHARMACEUTICAL SCIENCES
Ratings and Reviews
About the Editor
Annette Doherty
Affiliations and Expertise
Pfizer Global R&D, Sandwich Laboratories, United Kingdom
Request Quote
Tax Exemption
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.